All In Biotech

NDA 219884 · Acadia Pharms INC

Daybue Stix

Trofinetide · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Dec 11, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

12

4 Phase 3, 0 recruiting

FAERS reports

655

189 serious, 8 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 4, 2026.

DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. ( 1 )

Mechanism: The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 11, 2025 Original approval · Type 3 - New Dosage Form OrphanLetter
5 products under this application
  • DAYBUE STIX · TROFINETIDE 8000MG/PACKET · FOR SOLUTION, ORAL · Prescription
  • DAYBUE STIX · TROFINETIDE 5000MG/PACKET · FOR SOLUTION, ORAL · Prescription
  • DAYBUE STIX · TROFINETIDE 10,000MG · SOLUTION, ORAL · Prescription
  • DAYBUE STIX · TROFINETIDE 6000MG/PACKET · FOR SOLUTION, ORAL · Prescription
  • DAYBUE STIX · TROFINETIDE 12,000MG · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Trofinetide" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea382
  • underdose125
  • vomiting105
  • seizure78
  • constipation76
  • product use complaint64
  • intentional dose omission54
  • flatulence48
  • weight decreased41
  • abdominal discomfort39
  • weight increased38
  • inappropriate schedule of product administration36

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20233
20245
202518
2026628

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 17 on PubMed

Sponsor: Acadia Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.